Search

Your search keyword '"Bardai, Abdenasser"' showing total 16 results
Start Over Author "Bardai, Abdenasser"
16 results on '"Bardai, Abdenasser"'

2. Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome

Author

Gray, Belinda, Baruteau, Alban-Elouen, Antolin, Albert A, Pittman, Alan, Sarganas, Giselle, Molokhia, Mariam, Blom, Marieke T, Bastiaenen, Rachel, Bardai, Abdenasser, Priori, Silvia G, Napolitano, Carlo, Weeke, Peter E, Shakir, Saad A, Haverkamp, Wilhelm, Mestres, Jordi, Winkel, Bo, Witney, Adam A, Chis-Ster, Irina, Sangaralingam, Ajanthah, Camm, A John, Tfelt-Hansen, Jacob, Roden, Dan M, Tan, Hanno L, Garbe, Edeltraut, Sturkenboom, Miriam, Behr, Elijah R, Gray, Belinda, Baruteau, Alban-Elouen, Antolin, Albert A, Pittman, Alan, Sarganas, Giselle, Molokhia, Mariam, Blom, Marieke T, Bastiaenen, Rachel, Bardai, Abdenasser, Priori, Silvia G, Napolitano, Carlo, Weeke, Peter E, Shakir, Saad A, Haverkamp, Wilhelm, Mestres, Jordi, Winkel, Bo, Witney, Adam A, Chis-Ster, Irina, Sangaralingam, Ajanthah, Camm, A John, Tfelt-Hansen, Jacob, Roden, Dan M, Tan, Hanno L, Garbe, Edeltraut, Sturkenboom, Miriam, and Behr, Elijah R

Abstract

BACKGROUND: Acquired long QT syndrome (aLQTS) is a serious unpredictable adverse drug reaction. Pharmacogenomic markers may predict risk.METHODS: Among 153 aLQTS patients (mean age 58 years [range, 14-88], 98.7% White, 85.6% symptomatic), computational methods identified proteins interacting most significantly with 216 QT-prolonging drugs. All cases underwent sequencing of 31 candidate genes arising from this analysis or associating with congenital LQTS. Variants were filtered using a minor allele frequency <1% and classified for susceptibility for aLQTS. Gene-burden analyses were then performed comparing the primary cohort to control exomes (n=452) and an independent replication aLQTS exome sequencing cohort.RESULTS: In 25.5% of cases, at least one rare variant was identified: 22.2% of cases carried a rare variant in a gene associated with congenital LQTS, and in 4% of cases that variant was known to be pathogenic or likely pathogenic for congenital LQTS; 7.8% cases carried a cytochrome-P450 (CYP) gene variant. Of 12 identified CYP variants, 11 (92%) were in an enzyme known to metabolize at least one culprit drug to which the subject had been exposed. Drug-drug interactions that affected culprit drug metabolism were found in 19% of cases. More than one congenital LQTS variant, CYP gene variant, or drug interaction was present in 7.8% of cases. Gene-burden analyses of the primary cohort compared to control exomes (n=452), and an independent replication aLQTS exome sequencing cohort (n=67) and drug-tolerant controls (n=148) demonstrated an increased burden of rare (minor allele frequency<0.01) variants in CYP genes but not LQTS genes.CONCLUSIONS: Rare susceptibility variants in CYP genes are emerging as potentially important pharmacogenomic risk markers for aLQTS and could form part of personalized medicine approaches in the future.

Published
2022

3. Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome

Author

Data Science & Biostatistiek, Child Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Gray, Belinda, Baruteau, Alban-Elouen, Antolin, Albert A, Pittman, Alan, Sarganas, Giselle, Molokhia, Mariam, Blom, Marieke T, Bastiaenen, Rachel, Bardai, Abdenasser, Priori, Silvia G, Napolitano, Carlo, Weeke, Peter E, Shakir, Saad A, Haverkamp, Wilhelm, Mestres, Jordi, Winkel, Bo, Witney, Adam A, Chis-Ster, Irina, Sangaralingam, Ajanthah, Camm, A John, Tfelt-Hansen, Jacob, Roden, Dan M, Tan, Hanno L, Garbe, Edeltraut, Sturkenboom, Miriam, Behr, Elijah R, Data Science & Biostatistiek, Child Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Gray, Belinda, Baruteau, Alban-Elouen, Antolin, Albert A, Pittman, Alan, Sarganas, Giselle, Molokhia, Mariam, Blom, Marieke T, Bastiaenen, Rachel, Bardai, Abdenasser, Priori, Silvia G, Napolitano, Carlo, Weeke, Peter E, Shakir, Saad A, Haverkamp, Wilhelm, Mestres, Jordi, Winkel, Bo, Witney, Adam A, Chis-Ster, Irina, Sangaralingam, Ajanthah, Camm, A John, Tfelt-Hansen, Jacob, Roden, Dan M, Tan, Hanno L, Garbe, Edeltraut, Sturkenboom, Miriam, and Behr, Elijah R

Published
2022

4. Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome

Author

Gray, Belinda, primary, Baruteau, Alban-Elouen, additional, Antolin, Albert A., additional, Pittman, Alan, additional, Sarganas, Giselle, additional, Molokhia, Mariam, additional, Blom, Marieke T., additional, Bastiaenen, Rachel, additional, Bardai, Abdenasser, additional, Priori, Silvia G., additional, Napolitano, Carlo, additional, Weeke, Peter E., additional, Shakir, Saad A., additional, Haverkamp, Wilhelm, additional, Mestres, Jordi, additional, Winkel, Bo, additional, Witney, Adam A., additional, Chis-Ster, Irina, additional, Sangaralingam, Ajanthah, additional, Camm, A. John, additional, Tfelt-Hansen, Jacob, additional, Roden, Dan M., additional, Tan, Hanno L., additional, Garbe, Edeltraut, additional, Sturkenboom, Miriam, additional, and Behr, Elijah R., additional

Published
2022
Full Text
View/download PDF

8. Women have lower chances thanmen to be resuscitated and survive out-of-hospital cardiac arrest

Author

Blom, Marieke T., Oving, Iris, Berdowski, Jocelyn, van Valkengoed, Irene G.M., Bardai, Abdenasser, and Tan, Hanno L.

Abstract

Aims: Previous studies on sex differences in out-of-hospital cardiac arrest (OHCA) had limited scope and yielded conflicting results. We aimed to provide a comprehensive overall view on sex differences in care utilization, and outcome of OHCA. Methods and results: We performed a population-based cohort-study, analysing all emergency medical service (EMS) treated resuscitation attempts in one province of the Netherlands (2006–2012). We calculated odds ratios (ORs) for the association of sex and chance of a resuscitation attempt by EMS, shockable initial rhythm (SIR), and in-hospital treatment using logistic regression analysis. Additionally, we provided an overview of sex differences in overall survival and survival at successive stages of care, in the entire study population and in patients with SIR. We identified 5717 EMS-treated OHCAs (28.0% female). Women with OHCA were less likely than men to receive a resuscitation attempt by a bystander (67.9% vs. 72.7%; P < 0.001), even when OHCA was witnessed (69.2% vs. 73.9%; P < 0.001). Women who were resuscitated had lower odds than men for overall survival to hospital discharge [OR 0.57; 95% confidence interval (CI) 0.48–0.67; 12.5% vs. 20.1%; P < 0.001], survival from OHCA to hospital admission (OR 0.88; 95% CI 0.78–0.99; 33.6% vs. 36.6%; P = 0.033), and survival from hospital admission to discharge (OR 0.49, 95% CI 0.40– 0.60; 33.1% vs. 51.7%). This was explained by a lower rate of SIR in women (33.7% vs. 52.7%; P < 0.001). After adjustment for resuscitation parameters, female sex remained independently associated with lower SIR rate. Conclusion: In case of OHCA, women are less often resuscitated by bystanders than men. When resuscitation is attempted, women have lower survival rates at each successive stage of care. These sex gaps are likely explained by lower rate of SIR in women, which can only partly be explained by resuscitation characteristics.

Published
2019

10. High haemoglobin A1c level is a possible risk factor for ventricular fibrillation in sudden cardiac arrest among non-diabetic individuals in the general population.

Author

Dongen, Laura H van, Blom, Marieke T, Bardai, Abdenasser, Homma, Paulien C M, Beulens, Joline W J, Heijden, Amber A van der, Elders, Petra, Tan, Hanno L, van Dongen, Laura H, van der Heijden, Amber A, and ESCAPE-NET Investigators

Subjects
RESEARCH, RESEARCH methodology, CASE-control method, MEDICAL cooperation, EVALUATION research, COMPARATIVE studies, CARDIAC arrest, VENTRICULAR fibrillation
Abstract

Aims: This study aimed to establish whether higher levels of glycated haemoglobin (HbA1c) are associated with increased sudden cardiac arrest (SCA) risk in non-diabetic individuals.Methods and Results: Case-control study in non-diabetic individuals (HbA1c < 6.5%) in the Netherlands. Cases were SCA patients with electrocardiogram (ECG)-documented ventricular fibrillation (VF, the predominant cause of SCA) and HbA1c measurements immediately after VF, prospectively included in September 2009-December 2012. Controls (up to 10 per case) were age/sex-matched non-SCA individuals, included in July 2006-November 2007. We studied 306 cases (56.4 ± 6.8 years, 79.1% male) and 1722 controls (54.0 ± 6.8 years, 64.8% male). HbA1c levels were higher in cases than in controls (5.8 ± 0.3% vs. 5.4 ± 0.3%, P < 0.001). The proportion of increased HbA1c (≥5.7%) was 63.1% in cases and 19.3% in controls (P < 0.001). Multivariate regression models indicated that increased HbA1c was associated with a > six-fold increased VF risk [adjusted odds ratio (ORadj) 6.74 (5.00-9.09)] and that 0.1% increase in HbA1c level was associated with 1.4-fold increase in VF risk, independent of concomitant cardiovascular risk factors. Increased VF risk at higher HbA1c is associated with acute myocardial infarction (MI) as cause of VF [OR 1.14 (1.04-1.24)], but the association between HbA1c and VF was similar in non-MI patients [OR 1.32 (1.21-1.44)] and MI patients [OR 1.47 (1.37-1.58)].Conclusion: Among non-diabetic individuals, risk of VF increased with rising HbA1c levels, independent of concomitant cardiovascular disease. Future studies should establish whether HbA1c level may be used as biomarker to recognize individuals at risk for VF. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

11. Identification of a Sudden Cardiac Death Susceptibility Locus at 2q24.2 through Genome-Wide Association in European Ancestry Individuals

Author

Arking, DE, Junttila, MJ, Goyette, P, Huertas-Vazquez, A, Eijgelsheim, Mark, Blom, MT, Newton-Cheh, C, Reinier, K, Teodorescu, C, Uy-Evanado, A, Carter-Monroe, N, Kaikkonen, KS, Kortelainen, ML, Boucher, G, Lagace, C, Moes, A (Anna), Zhao, XQ, Kolodgie, F, Rivadeneira, Fernando, Hofman, Bert, Witteman, JCM, Uitterlinden, André, Marsman, RF, Pazoki, Raha, Bardai, Abdenasser, Koster, RW, Dehghan, Abbas, Hwang, SJ, Bhatnagar, P, Post, W, Hilton, G, Prineas, RJ, Li, M, Kottgen, A, Ehret, G, Boerwinkle, E, Coresh, J, Kao, WHL, Psaty, BM, Tomaselli, GF, Sotoodehnia, N, Siscovick, DS, Burke, GL, Marban, E, Spooner, PM, Cupples, LA, Jui, J, Gunson, K, Kesaniemi, YA, Wilde, AAM, Tardif, JC, O'Donnell, CJ, Bezzina, CR, Virmani, R, Stricker, Bruno, Tan, HL, Albert, CM, Chakravarti, A, Rioux, JD, Huikuri, HV, Chugh, SS, Arking, DE, Junttila, MJ, Goyette, P, Huertas-Vazquez, A, Eijgelsheim, Mark, Blom, MT, Newton-Cheh, C, Reinier, K, Teodorescu, C, Uy-Evanado, A, Carter-Monroe, N, Kaikkonen, KS, Kortelainen, ML, Boucher, G, Lagace, C, Moes, A (Anna), Zhao, XQ, Kolodgie, F, Rivadeneira, Fernando, Hofman, Bert, Witteman, JCM, Uitterlinden, André, Marsman, RF, Pazoki, Raha, Bardai, Abdenasser, Koster, RW, Dehghan, Abbas, Hwang, SJ, Bhatnagar, P, Post, W, Hilton, G, Prineas, RJ, Li, M, Kottgen, A, Ehret, G, Boerwinkle, E, Coresh, J, Kao, WHL, Psaty, BM, Tomaselli, GF, Sotoodehnia, N, Siscovick, DS, Burke, GL, Marban, E, Spooner, PM, Cupples, LA, Jui, J, Gunson, K, Kesaniemi, YA, Wilde, AAM, Tardif, JC, O'Donnell, CJ, Bezzina, CR, Virmani, R, Stricker, Bruno, Tan, HL, Albert, CM, Chakravarti, A, Rioux, JD, Huikuri, HV, and Chugh, SS

Abstract

Sudden cardiac death (SCD) continues to be one of the leading causes of mortality worldwide, with an annual incidence estimated at 250,000-300,000 in the United States and with the vast majority occurring in the setting of coronary disease. We performed a genome-wide association meta-analysis in 1,283 SCD cases and >20,000 control individuals of European ancestry from 5 studies, with follow-up genotyping in up to 3,119 SCD cases and 11,146 controls from 11 European ancestry studies, and identify the BAZ2B locus as associated with SCD (P = 1.8610 210). The risk allele, while ancestral, has a frequency of similar to 1.4%, suggesting strong negative selection and increases risk for SCD by 1.92-fold per allele (95% CI 1.57-2.34). We also tested the role of 49 SNPs previously implicated in modulating electrocardiographic traits (QRS, QT, and RR intervals). Consistent with epidemiological studies showing increased risk of SCD with prolonged QRS/QT intervals, the interval-prolonging alleles are in aggregate associated with increased risk for SCD (P = 0.006).

Published
2011

12. Implantable Cardioverter-Defibrillators Have Reduced the Incidence of Resuscitation for Out-of-Hospital Cardiac Arrest Caused by Lethal Arrhythmias

Author

Hulleman, Michiel, primary, Berdowski, Jocelyn, additional, de Groot, Joris R., additional, van Dessel, Pascal F.H.M., additional, Borleffs, C. Jan Willem, additional, Blom, Marieke T., additional, Bardai, Abdenasser, additional, de Cock, Carel C., additional, Tan, Hanno L., additional, Tijssen, Jan G.P., additional, and Koster, Rudolph W., additional

Published
2012
Full Text
View/download PDF

13. High haemoglobin A1c level is a possible risk factor for ventricular fibrillation in sudden cardiac arrest among non-diabetic individuals in the general population

Author

van Dongen, Laura H, Blom, Marieke T, Bardai, Abdenasser, Homma, Paulien C M, Beulens, Joline W J, van der Heijden, Amber A, Elders, Petra, and Tan, Hanno L

Subjects
3. Good health
Abstract

Aims This study aimed to establish whether higher levels of glycated haemoglobin (HbA1c) are associated with increased sudden cardiac arrest (SCA) risk in non-diabetic individuals. Methods and results Case–control study in non-diabetic individuals (HbA1c P P  six-fold increased VF risk [adjusted odds ratio (ORadj) 6.74 (5.00–9.09)] and that 0.1% increase in HbA1c level was associated with 1.4-fold increase in VF risk, independent of concomitant cardiovascular risk factors. Increased VF risk at higher HbA1c is associated with acute myocardial infarction (MI) as cause of VF [OR 1.14 (1.04–1.24)], but the association between HbA1c and VF was similar in non-MI patients [OR 1.32 (1.21–1.44)] and MI patients [OR 1.47 (1.37–1.58)]. Conclusion Among non-diabetic individuals, risk of VF increased with rising HbA1c levels, independent of concomitant cardiovascular disease. Future studies should establish whether HbA1c level may be used as biomarker to recognize individuals at risk for VF.

14. High haemoglobin A1c level is a possible risk factor for ventricular fibrillation in sudden cardiac arrest among non-diabetic individuals in the general population

Author

van Dongen, Laura H, Blom, Marieke T, Bardai, Abdenasser, Homma, Paulien C M, Beulens, Joline W J, van der Heijden, Amber A, Elders, Petra, and Tan, Hanno L

Subjects
3. Good health
Abstract

Aims This study aimed to establish whether higher levels of glycated haemoglobin (HbA1c) are associated with increased sudden cardiac arrest (SCA) risk in non-diabetic individuals. Methods and results Case–control study in non-diabetic individuals (HbA1c < 6.5%) in the Netherlands. Cases were SCA patients with electrocardiogram (ECG)-documented ventricular fibrillation (VF, the predominant cause of SCA) and HbA1c measurements immediately after VF, prospectively included in September 2009–December 2012. Controls (up to 10 per case) were age/sex-matched non-SCA individuals, included in July 2006–November 2007. We studied 306 cases (56.4 ± 6.8 years, 79.1% male) and 1722 controls (54.0 ± 6.8 years, 64.8% male). HbA1c levels were higher in cases than in controls (5.8 ± 0.3% vs. 5.4 ± 0.3%, P < 0.001). The proportion of increased HbA1c (≥5.7%) was 63.1% in cases and 19.3% in controls (P < 0.001). Multivariate regression models indicated that increased HbA1c was associated with a > six-fold increased VF risk [adjusted odds ratio (ORadj) 6.74 (5.00–9.09)] and that 0.1% increase in HbA1c level was associated with 1.4-fold increase in VF risk, independent of concomitant cardiovascular risk factors. Increased VF risk at higher HbA1c is associated with acute myocardial infarction (MI) as cause of VF [OR 1.14 (1.04–1.24)], but the association between HbA1c and VF was similar in non-MI patients [OR 1.32 (1.21–1.44)] and MI patients [OR 1.47 (1.37–1.58)]. Conclusion Among non-diabetic individuals, risk of VF increased with rising HbA1c levels, independent of concomitant cardiovascular disease. Future studies should establish whether HbA1c level may be used as biomarker to recognize individuals at risk for VF.

15. High haemoglobin A1c level is a possible risk factor for ventricular fibrillation in sudden cardiac arrest among non-diabetic individuals in the general population.

Author

van Dongen LH, Blom MT, Bardai A, Homma PCM, Beulens JWJ, van der Heijden AA, Elders P, and Tan HL

Subjects
Case-Control Studies, Female, Glycated Hemoglobin, Humans, Male, Netherlands epidemiology, Risk Factors, Death, Sudden, Cardiac epidemiology, Ventricular Fibrillation diagnosis, Ventricular Fibrillation epidemiology
Abstract

Aims: This study aimed to establish whether higher levels of glycated haemoglobin (HbA1c) are associated with increased sudden cardiac arrest (SCA) risk in non-diabetic individuals., Methods and Results: Case-control study in non-diabetic individuals (HbA1c < 6.5%) in the Netherlands. Cases were SCA patients with electrocardiogram (ECG)-documented ventricular fibrillation (VF, the predominant cause of SCA) and HbA1c measurements immediately after VF, prospectively included in September 2009-December 2012. Controls (up to 10 per case) were age/sex-matched non-SCA individuals, included in July 2006-November 2007. We studied 306 cases (56.4 ± 6.8 years, 79.1% male) and 1722 controls (54.0 ± 6.8 years, 64.8% male). HbA1c levels were higher in cases than in controls (5.8 ± 0.3% vs. 5.4 ± 0.3%, P < 0.001). The proportion of increased HbA1c (≥5.7%) was 63.1% in cases and 19.3% in controls (P < 0.001). Multivariate regression models indicated that increased HbA1c was associated with a > six-fold increased VF risk [adjusted odds ratio (ORadj) 6.74 (5.00-9.09)] and that 0.1% increase in HbA1c level was associated with 1.4-fold increase in VF risk, independent of concomitant cardiovascular risk factors. Increased VF risk at higher HbA1c is associated with acute myocardial infarction (MI) as cause of VF [OR 1.14 (1.04-1.24)], but the association between HbA1c and VF was similar in non-MI patients [OR 1.32 (1.21-1.44)] and MI patients [OR 1.47 (1.37-1.58)]., Conclusion: Among non-diabetic individuals, risk of VF increased with rising HbA1c levels, independent of concomitant cardiovascular disease. Future studies should establish whether HbA1c level may be used as biomarker to recognize individuals at risk for VF., (© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2020
Full Text
View/download PDF

16. Transaortic Aortic Valve Implantation in 100 Patients: Follow-up to 3 Years.

Author

Cocchieri R, Koh EY, Wollersheim LW, Meregalli PG, Bardai A, Bouma BJ, and de Mol BA

Subjects
Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Male, Retrospective Studies, Survival Analysis, Treatment Outcome, Aortic Valve Stenosis surgery, Heart Valve Prosthesis Implantation instrumentation, Heart Valve Prosthesis Implantation methods
Abstract

Objective: Transaortic aortic valve implantation (TAo-AVI) through the ascending aorta is a novel technique and is used as an alternative in patients with poor femoral access. Although early results have been promising, no midterm data have been published yet. To determine whether this approach is an acceptable treatment option, we analyzed the first 100 cases performed at our institution with a follow-up to 3 years., Methods: Between July 2011 and January 2015, a total of 100 patients with high-risk or inoperable aortic valve stenosis were treated with TAo-AVI. Preoperative patient data were collected and analyzed retrospectively. All surviving patients were seen for clinical and echocardiographic examination for follow-up., Results: Median follow-up was 15 months. Device success was accomplished in 94 patients (94%). There were no access site complications. The 30-day mortality rate was 9%. Stroke occurred in a total of six patients (6%). Survival at 1-, 2-, and 3 years was 75%, 62%, and 58%, respectively., Conclusions: Our results show that TAo-AVI is a promising alternative to transapical implantation for treating severe inoperable aortic valve stenosis.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results